Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) has announced the appointment of Renee Gala as the President and Chief Executive Officer, effective August 11, 2025. Gala, who currently serves as the President and Chief Operating Officer, will succeed co-founder Bruce Cozadd, who will retire as CEO but remain as Chairperson of the Board of Directors.
Gala's promotion reflects a key milestone in the company's long-term succession planning process. Since her appointment as President and COO in October 2023, Jazz Pharmaceuticals has seen significant growth under her leadership. Total revenue has increased by almost 90%, and Gala has played a critical role in driving the company's ongoing transformation, diversifying its portfolio, and establishing a pipeline for future growth.
In addition to her financial expertise, Gala's leadership has been instrumental in architecting a business development strategy that has driven the company's growth. She brings over 30 years of experience in finance, strategy, corporate development, and commercialization to her new role.
Bruce Cozadd expressed immense pride in the company's journey and its evolution into an innovative biopharma company under Gala's leadership. He highlighted her critical role in the company's transformation into a high-growth biopharmaceutical company with a strong R&D pipeline and robust commercial operations.
As Jazz Pharmaceuticals prepares for this leadership transition, Cozadd will continue to serve as Chairperson of the Board, providing strategic input as the company executes its growth strategy.
Gala's proven leadership and progressive experience in key areas across the life sciences industry position her as an exceptional leader to drive Jazz Pharmaceuticals' continued success. The company's Board of Directors is highly confident in Gala's ability to not only operate the business but also serve as a catalyst in driving long-term growth.
The company's focus on delivering value and its commitment to patient-centricity and mutual respect align with Gala's vision for the company. Her appointment marks an important moment for Jazz Pharmaceuticals as it looks to capitalize on its market-leading portfolio of medicines, promising pipeline, and strong financial position to pursue new opportunities and drive greater value for patients and shareholders.
Gala's extensive experience and track record of driving high performance and change at Jazz Pharmaceuticals position her as the clear standout among a field of highly capable and qualified candidates, according to Rick Winningham, lead independent director.
Jazz Pharmaceuticals is a global biopharma company dedicated to innovating and transforming the lives of patients and their families. The company's diverse portfolio of marketed medicines includes leading therapies for sleep disorders and epilepsy, as well as a growing portfolio of cancer treatments. Jazz's patient-focused and science-driven approach powers pioneering research and development advancements across its robust pipeline of innovative therapeutics in oncology and neuroscience. As a result of these announcements, the company's shares have moved 2.26% on the market, and are now trading at a price of $111.60. Check out the company's full 8-K submission here.
